| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0049-3848(19)30367-6 |
| P698 | PubMed publication ID | 31477228 |
| P2093 | author name string | Dominique Farge | |
| Ludovic Doucet | |||
| Christine Le Maignan | |||
| Corinne Frere | |||
| P2860 | cites work | Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group | Q73190394 |
| First-time use of newer oral contraceptives and the risk of venous thromboembolism | Q73825302 | ||
| Incidence and mortality of venous thrombosis: a population-based study | Q79969827 | ||
| Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study | Q81588010 | ||
| Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics | Q82300137 | ||
| Sex-specific risk factors for recurrent venous thromboembolism | Q82594467 | ||
| The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study | Q87317877 | ||
| Statins, aspirin and risk of thromboembolic events in ovarian cancer patients | Q87446984 | ||
| Haematological malignancies in pregnancy: An overview with an emphasis on thrombotic risks | Q88011922 | ||
| Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases-an analysis of 992 stimulations | Q88993307 | ||
| The impact of malignancy on response to ovarian stimulation for fertility preservation: a meta-analysis | Q90020859 | ||
| Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | Q90240985 | ||
| Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH | Q90357781 | ||
| The best direct-acting oral anticoagulant for treatment of venous thromboembolism? | Q90593418 | ||
| Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study | Q90637386 | ||
| Combined oral contraceptives: venous thrombosis | Q24198113 | ||
| Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis | Q24622035 | ||
| Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis | Q24647720 | ||
| Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 | Q28266410 | ||
| Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial | Q28289262 | ||
| Tamoxifen and risk of idiopathic venous thromboembolism | Q28368257 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. | Q31024426 | ||
| Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. | Q33365697 | ||
| Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer | Q33399333 | ||
| Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis | Q33422297 | ||
| Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment | Q33422300 | ||
| Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. | Q33952753 | ||
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study | Q34037065 | ||
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | Q34382805 | ||
| Two clinical phenotypes in polycythemia vera | Q34415448 | ||
| Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation | Q34428728 | ||
| Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report | Q34513594 | ||
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism | Q34655742 | ||
| Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update | Q34743455 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Incidence and predictors of venous thromboembolism after debulking surgery for epithelial ovarian cancer | Q35016892 | ||
| Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression | Q35848857 | ||
| Fertility preservation in reproductive-age women facing gonadotoxic treatments | Q35934317 | ||
| Development and validation of a predictive model for chemotherapy-associated thrombosis | Q36657982 | ||
| Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review | Q36797819 | ||
| Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study | Q36887503 | ||
| Fertility Preservation for the Young Breast Cancer Patient | Q36936518 | ||
| Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies | Q37303936 | ||
| The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study | Q37305295 | ||
| Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy | Q37330723 | ||
| Venous thromboembolism in pregnancy | Q37396642 | ||
| SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). | Q37475179 | ||
| Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism | Q37588677 | ||
| Pregnancy-associated venous thromboembolism: prevention and treatment | Q37945863 | ||
| Haematological cancers in pregnancy | Q37983218 | ||
| Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the Registro Informatizado de la Enfermedad Trombo Embólica Registry | Q38012314 | ||
| Venous thromboembolism associated with pregnancy and hormonal therapy | Q38041799 | ||
| Perioperative care in gynecologic oncology | Q38072561 | ||
| Fertility preservation in women | Q38156039 | ||
| Development of venous thromboembolism (VTE) in patients undergoing surgery for brain tumors: results from a single center over a 10 year period | Q38297551 | ||
| Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases | Q38429239 | ||
| Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis | Q38439334 | ||
| Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study | Q38445263 | ||
| Venous thromboembolism in brain tumor patients | Q38644595 | ||
| Sex-specific differences in the presenting location of a first venous thromboembolism. | Q38821459 | ||
| International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer | Q38979052 | ||
| Unintended Pregnancy: A Systematic Review of Contraception Use and Counseling in Women With Cancer. | Q39185897 | ||
| Sex difference in risk of second but not of first venous thrombosis: paradox explained | Q39328528 | ||
| Risk of Cerebral Venous Thrombosis in Obese Women. | Q39922205 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| Fertility preservation in children, adolescents, and young adults with cancer: Quality of clinical practice guidelines and variations in recommendations | Q40755950 | ||
| Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer | Q40810746 | ||
| Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer | Q40912008 | ||
| Comparison of bleeding risks related to venous thromboembolism prophylaxis in laparoscopic vs open colorectal cancer surgery: a multicenter study in Japanese patients | Q40973973 | ||
| Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. | Q41552439 | ||
| The influence of comorbidity on mortality in ovarian cancer patients | Q42226443 | ||
| Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer | Q42281643 | ||
| Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen | Q43233449 | ||
| Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles | Q43712296 | ||
| Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
| Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations | Q44006721 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| Platelet activation and inhibition in polycythemia vera and essential thrombocythemia | Q44117506 | ||
| Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q44495734 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda | Q44635849 | ||
| The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy | Q44735545 | ||
| Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. | Q44823539 | ||
| Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study | Q45061360 | ||
| Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. | Q45944471 | ||
| Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). | Q46019608 | ||
| How I treat pregnancy-related venous thromboembolism | Q46326576 | ||
| Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study | Q46337264 | ||
| Effective method for emergency fertility preservation: random-start controlled ovarian stimulation | Q46459277 | ||
| Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study | Q46570403 | ||
| Venous thromboembolism in ovarian cancer | Q46888024 | ||
| Uterine bleeding during anticoagulation in women with venous thromboembolism | Q47338213 | ||
| Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism | Q47682974 | ||
| Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients | Q48393708 | ||
| Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry | Q48744844 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism | Q49168967 | ||
| Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study | Q50042051 | ||
| Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. | Q50490968 | ||
| Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis. | Q50967725 | ||
| Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. | Q52932649 | ||
| Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. | Q53214879 | ||
| Gender differences in cancer patients with acute venous thromboembolism. | Q54098263 | ||
| Risk factors for deep venous thrombosis in women with ovarian cancer. | Q55249384 | ||
| New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation | Q57091434 | ||
| Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type | Q57091648 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges | Q61797453 | ||
| Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) | Q61860158 | ||
| Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival | Q61929860 | ||
| Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study | Q73190388 | ||
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | S47-S53 | |
| P577 | publication date | 2019-09-01 | |
| P1433 | published in | Thrombosis Research | Q15758741 |
| P1476 | title | Women, thrombosis, and cancer | |
| P478 | volume | 181 Suppl 1 |
Search more.